Global Gastroesophageal Reflux Disease Therapeutics Market Size, Status and Forecast 2020-2026

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered: Ranking by Gastroesophageal Reflux Disease Therapeutics Revenue
• 1.4 Market by Type
  • 1.4.1 Global Gastroesophageal Reflux Disease Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
  • 1.4.2 Antacids
  • 1.4.3 H2 Receptor Blockers
  • 1.4.4 Proton Pump Inhibitors (PPIs)
  • 1.4.5 Pro-kinetic Agents
  • 1.4.6 Others
• 1.5 Market by Application
  • 1.5.1 Global Gastroesophageal Reflux Disease Therapeutics Market Share by Application: 2020 VS 2026
  • 1.5.2 Hospital Pharmacy
  • 1.5.3 Drug Stores
  • 1.5.4 General Stores
  • 1.5.5 Supermarkets
• 1.6 Study Objectives
• 1.7 Years Considered

2 Global Growth Trends

• 2.1 Global Gastroesophageal Reflux Disease Therapeutics Market Perspective (2015-2026)
• 2.2 Global Gastroesophageal Reflux Disease Therapeutics Growth Trends by Regions
  • 2.2.1 Gastroesophageal Reflux Disease Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
  • 2.2.2 Gastroesophageal Reflux Disease Therapeutics Historic Market Share by Regions (2015-2020)
  • 2.2.3 Gastroesophageal Reflux Disease Therapeutics Forecasted Market Size by Regions (2021-2026)
• 2.3 Industry Trends and Growth Strategy
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Porter’s Five Forces Analysis
  • 2.3.5 Gastroesophageal Reflux Disease Therapeutics Market Growth Strategy
  • 2.3.6 Primary Interviews with Key Gastroesophageal Reflux Disease Therapeutics Players (Opinion Leaders)

3 Competition Landscape by Key Players

• 3.1 Global Top Gastroesophageal Reflux Disease Therapeutics Players by Market Size
  • 3.1.1 Global Top Gastroesophageal Reflux Disease Therapeutics Players by Revenue (2015-2020)
  • 3.1.2 Global Gastroesophageal Reflux Disease Therapeutics Revenue Market Share by Players (2015-2020)
  • 3.1.3 Global Gastroesophageal Reflux Disease Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.2 Global Gastroesophageal Reflux Disease Therapeutics Market Concentration Ratio
  • 3.2.1 Global Gastroesophageal Reflux Disease Therapeutics Market Concentration Ratio (CR5 and HHI)
  • 3.2.2 Global Top 10 and Top 5 Companies by Gastroesophageal Reflux Disease Therapeutics Revenue in 2019
• 3.3 Gastroesophageal Reflux Disease Therapeutics Key Players Head office and Area Served
• 3.4 Key Players Gastroesophageal Reflux Disease Therapeutics Product Solution and Service
• 3.5 Date of Enter into Gastroesophageal Reflux Disease Therapeutics Market
• 3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)

• 4.1 Global Gastroesophageal Reflux Disease Therapeutics Historic Market Size by Type (2015-2020)
• 4.2 Global Gastroesophageal Reflux Disease Therapeutics Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)

• 5.1 Global Gastroesophageal Reflux Disease Therapeutics Market Size by Application (2015-2020)
• 5.2 Global Gastroesophageal Reflux Disease Therapeutics Forecasted Market Size by Application (2021-2026)

6 North America

• 6.1 North America Gastroesophageal Reflux Disease Therapeutics Market Size (2015-2020)
• 6.2 Gastroesophageal Reflux Disease Therapeutics Key Players in North America (2019-2020)
• 6.3 North America Gastroesophageal Reflux Disease Therapeutics Market Size by Type (2015-2020)
• 6.4 North America Gastroesophageal Reflux Disease Therapeutics Market Size by Application (2015-2020)

7 Europe

• 7.1 Europe Gastroesophageal Reflux Disease Therapeutics Market Size (2015-2020)
• 7.2 Gastroesophageal Reflux Disease Therapeutics Key Players in Europe (2019-2020)
• 7.3 Europe Gastroesophageal Reflux Disease Therapeutics Market Size by Type (2015-2020)
• 7.4 Europe Gastroesophageal Reflux Disease Therapeutics Market Size by Application (2015-2020)

8 China

• 8.1 China Gastroesophageal Reflux Disease Therapeutics Market Size (2015-2020)
• 8.2 Gastroesophageal Reflux Disease Therapeutics Key Players in China (2019-2020)
• 8.3 China Gastroesophageal Reflux Disease Therapeutics Market Size by Type (2015-2020)
• 8.4 China Gastroesophageal Reflux Disease Therapeutics Market Size by Application (2015-2020)

9 Japan

• 9.1 Japan Gastroesophageal Reflux Disease Therapeutics Market Size (2015-2020)
• 9.2 Gastroesophageal Reflux Disease Therapeutics Key Players in Japan (2019-2020)
• 9.3 Japan Gastroesophageal Reflux Disease Therapeutics Market Size by Type (2015-2020)
• 9.4 Japan Gastroesophageal Reflux Disease Therapeutics Market Size by Application (2015-2020)

10 Southeast Asia

• 10.1 Southeast Asia Gastroesophageal Reflux Disease Therapeutics Market Size (2015-2020)
• 10.2 Gastroesophageal Reflux Disease Therapeutics Key Players in Southeast Asia (2019-2020)
• 10.3 Southeast Asia Gastroesophageal Reflux Disease Therapeutics Market Size by Type (2015-2020)
• 10.4 Southeast Asia Gastroesophageal Reflux Disease Therapeutics Market Size by Application (2015-2020)

11 India

• 11.1 India Gastroesophageal Reflux Disease Therapeutics Market Size (2015-2020)
• 11.2 Gastroesophageal Reflux Disease Therapeutics Key Players in India (2019-2020)
• 11.3 India Gastroesophageal Reflux Disease Therapeutics Market Size by Type (2015-2020)
• 11.4 India Gastroesophageal Reflux Disease Therapeutics Market Size by Application (2015-2020)

12 Central & South America

• 12.1 Central & South America Gastroesophageal Reflux Disease Therapeutics Market Size (2015-2020)
• 12.2 Gastroesophageal Reflux Disease Therapeutics Key Players in Central & South America (2019-2020)
• 12.3 Central & South America Gastroesophageal Reflux Disease Therapeutics Market Size by Type (2015-2020)
• 12.4 Central & South America Gastroesophageal Reflux Disease Therapeutics Market Size by Application (2015-2020)

13 Key Players Profiles

• 13.1 AstraZeneca
  • 13.1.1 AstraZeneca Company Details
  • 13.1.2 AstraZeneca Business Overview
  • 13.1.3 AstraZeneca Gastroesophageal Reflux Disease Therapeutics Introduction
  • 13.1.4 AstraZeneca Revenue in Gastroesophageal Reflux Disease Therapeutics Business (2015-2020))
  • 13.1.5 AstraZeneca Recent Development
• 13.2 Eisai
  • 13.2.1 Eisai Company Details
  • 13.2.2 Eisai Business Overview
  • 13.2.3 Eisai Gastroesophageal Reflux Disease Therapeutics Introduction
  • 13.2.4 Eisai Revenue in Gastroesophageal Reflux Disease Therapeutics Business (2015-2020)
  • 13.2.5 Eisai Recent Development
• 13.3 Takeda Pharmaceutical
  • 13.3.1 Takeda Pharmaceutical Company Details
  • 13.3.2 Takeda Pharmaceutical Business Overview
  • 13.3.3 Takeda Pharmaceutical Gastroesophageal Reflux Disease Therapeutics Introduction
  • 13.3.4 Takeda Pharmaceutical Revenue in Gastroesophageal Reflux Disease Therapeutics Business (2015-2020)
  • 13.3.5 Takeda Pharmaceutical Recent Development
• 13.4 GlaxoSmithKline
  • 13.4.1 GlaxoSmithKline Company Details
  • 13.4.2 GlaxoSmithKline Business Overview
  • 13.4.3 GlaxoSmithKline Gastroesophageal Reflux Disease Therapeutics Introduction
  • 13.4.4 GlaxoSmithKline Revenue in Gastroesophageal Reflux Disease Therapeutics Business (2015-2020)
  • 13.4.5 GlaxoSmithKline Recent Development
• 13.5 Johnson & Johnson
  • 13.5.1 Johnson & Johnson Company Details
  • 13.5.2 Johnson & Johnson Business Overview
  • 13.5.3 Johnson & Johnson Gastroesophageal Reflux Disease Therapeutics Introduction
  • 13.5.4 Johnson & Johnson Revenue in Gastroesophageal Reflux Disease Therapeutics Business (2015-2020)
  • 13.5.5 Johnson & Johnson Recent Development
• 13.6 Daewoong Pharmaceutical
  • 13.6.1 Daewoong Pharmaceutical Company Details
  • 13.6.2 Daewoong Pharmaceutical Business Overview
  • 13.6.3 Daewoong Pharmaceutical Gastroesophageal Reflux Disease Therapeutics Introduction
  • 13.6.4 Daewoong Pharmaceutical Revenue in Gastroesophageal Reflux Disease Therapeutics Business (2015-2020)
  • 13.6.5 Daewoong Pharmaceutical Recent Development
• 13.7 Ironwood Pharmaceuticals
  • 13.7.1 Ironwood Pharmaceuticals Company Details
  • 13.7.2 Ironwood Pharmaceuticals Business Overview
  • 13.7.3 Ironwood Pharmaceuticals Gastroesophageal Reflux Disease Therapeutics Introduction
  • 13.7.4 Ironwood Pharmaceuticals Revenue in Gastroesophageal Reflux Disease Therapeutics Business (2015-2020)
  • 13.7.5 Ironwood Pharmaceuticals Recent Development
• 13.8 Rottapharm Madaus
  • 13.8.1 Rottapharm Madaus Company Details
  • 13.8.2 Rottapharm Madaus Business Overview
  • 13.8.3 Rottapharm Madaus Gastroesophageal Reflux Disease Therapeutics Introduction
  • 13.8.4 Rottapharm Madaus Revenue in Gastroesophageal Reflux Disease Therapeutics Business (2015-2020)
  • 13.8.5 Rottapharm Madaus Recent Development
• 13.9 Peer Medical
  • 13.9.1 Peer Medical Company Details
  • 13.9.2 Peer Medical Business Overview
  • 13.9.3 Peer Medical Gastroesophageal Reflux Disease Therapeutics Introduction
  • 13.9.4 Peer Medical Revenue in Gastroesophageal Reflux Disease Therapeutics Business (2015-2020)
  • 13.9.5 Peer Medical Recent Development
• 13.10 Reviva Pharmaceuticals
  • 13.10.1 Reviva Pharmaceuticals Company Details
  • 13.10.2 Reviva Pharmaceuticals Business Overview
  • 13.10.3 Reviva Pharmaceuticals Gastroesophageal Reflux Disease Therapeutics Introduction
  • 13.10.4 Reviva Pharmaceuticals Revenue in Gastroesophageal Reflux Disease Therapeutics Business (2015-2020)
  • 13.10.5 Reviva Pharmaceuticals Recent Development

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
  • 15.1.2 Data Source
• 15.2 Disclaimer